Objective: To culture, isolate and identify new bunyavirus in Vero cell line.
Methods: Samples of 164 new bunyavirus positive by real time RT-PCR detection and well preserved serum specimens were selected from cases of fever, thrombocytopenia and leukopenia syndrome (FTLS) in Xinyang, Henan province in 2009 - 2011. These sera were cultured in Vero cell line and new bunyavirus were detected by observing cytopathic effect (CPE), Real-time RT-PCR, indirect immunofluorescence assay (IFA) and thin-section electron microscopy observation. A total of 10 positive PCR products were selected randomly for sequencing and the results were compared with sequence in Genbank.
Results: Among 164 FTLS serum specimens cultured in Vero cell line, no special CPE were observed and 67 strains (40.85%) were positive detected by Real-time RT-PCR. Nucleic acid similarity of 10 specimens were 97.8% - 100% and there's also a high similarity (> 99%) between specimens and new bunyavirus isolates (Accession No. HQ141600.1). Among 67 positive strains, 58 of them showed specific fluorescence particles by IFA. The viral particles were observed to be spheres with a diameter of 80 - 100 nm by electron microscopy.
Conclusion: Vero cell line is suitable for culture, isolation and identification of new bunyavirus.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Antiviral activity of an ACE2-Fc fusion protein against SARS-CoV-2 and its variants.
PLoS One
January 2025
Immunology and Immunotherapy Division, Center of Molecular Immunology (CIM), Havana, Cuba.
SARS-CoV-2 has continued spreading around the world in recent years since the initial outbreak in 2019, frequently developing into new variants with greater human infectious capacity. SARS-CoV-2 and its mutants use the angiotensin-converting enzyme 2 (ACE2) as a cellular entry receptor, which has triggered several therapeutic strategies against COVID-19 relying on the use of ACE2 recombinant proteins as decoy receptors. In this work, we propose an ACE2 silent Fc fusion protein (ACE2-hFcLALA) as a candidate therapy against COVID-19.
View Article and Find Full Text PDFEco-friendly Synthesis of Iron Oxide Nanoparticles Using Parietaria alsinifolia Extracts and Evaluation of Biological Applications.
Appl Biochem Biotechnol
January 2025
Department of Plant Sciences, Faculty of Biological Sciences, Quaid-I-Azam University Islamabad, Islamabad, 45320, Pakistan.
The current research was conducted to synthesize Parietaria alsinifolia-mediated iron oxide nanoparticles (P.A@FeONPs) using the green and eco-friendly protocol. The biosynthesized P.
View Article and Find Full Text PDFVisible-light-induced CO-releasing properties and cytotoxicity of a Ru(II) carbonyl complex containing 2-(pyridin-2-yl)-quinoxaline.
Dalton Trans
January 2025
Department of Chemistry, Faculty of Science, Cairo University, Gamma Street, Giza, Cairo 12613, Egypt.
The photo-induced CO-releasing properties of the dark-stable complex [RuCl(CO)L] (L = 2-(pyridin-2-yl)quinoxaline) were investigated under 468 nm light exposure in the presence and absence of biomolecules such as histidine, calf thymus DNA and hen egg white lysozyme. The CO release kinetics were consistent regardless of the presence of these biomolecules, suggesting that they did not influence the CO release mechanism. The quinoxaline ligand demonstrated exceptional cytotoxicity against human acute monocytic leukemia cells (THP-1), with evidence of potential DNA damage ascertained by comet assay, while it remained non-toxic to normal kidney epithelial cells derived from African green monkey (Vero) cell lines.
View Article and Find Full Text PDFDesign, synthesis, and biological evaluation of novel 2'-deoxy-2'-spirooxetane-7-deazapurine nucleoside analogs as anti-SARS-CoV-2 agents.
Antiviral Res
December 2024
State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Science, Guangzhou, 510530, China; Guangzhou Henovcom Bioscience Inc, 11 Kaiyuan Rd, Guangzhou, Guangdong, China. Electronic address:
Article Synopsis
- The COVID-19 pandemic, driven by the SARS-CoV-2 virus, poses ongoing health risks and highlights the need for new antiviral treatments due to the virus's ability to mutate.
- Researchers designed and synthesized new 2'-deoxy-2'-spirooxetane-7-deazapurine nucleoside analogs to inhibit the replication of SARS-CoV-2.
- Among these, nucleoside analog 11q showed the strongest antiviral effects, outperforming existing treatments like Remdesivir and indicating its potential as a future therapeutic option.
ATM/ATR-Mediated DNA Damage Response Facilitates SARS-CoV-2 Spike Protein-Induced Syncytium Formation.
J Med Virol
January 2025
Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, State Key Laboratory of Advanced Medical Materials and Devices, Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
Multinucleated cells are present in lung tissues of patients infected by SARS-CoV-2. Although the spike protein can cause the fusion of infected cells and ACE2-expressing cells to form syncytia and induce damage, how host cell responses to this damage and the role of DNA damage response (DDR) signals in cell fusion are still unclear. Therefore, we investigated the effect of SARS-CoV-2 spike protein on the fusion of homologous and heterologous cells expressing ACE2 in vitro models, focusing on the protein levels of ATR and ATM, the major kinases responding to DNA damage, and their substrates CHK1 and CHK2.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!